MT2024-06: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- at least 18 years old - relapsed following hematopoietic cell transplant (HCT) - unable to do strenuous activity but able to walk and able to carry out work of a light or sedentary nature, such as light house work, office work - Original alloHCT donor is available and willing to undergo apheresis - see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria

Exclusion Criteria:

- patients who have undergone more than one alloHCT - ongoing active acute or chronic Graft vs Host Disease (GVHD) and are taking systemic immunosuppressive agents - active CNS disease - active or uncontrolled viral, bacterial, or fungal infection - history of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, or breast) unless disease free for at least 3 years after the last definitive therapy - women who are pregnant or breast feeding

Conditions & Interventions

Interventions:
Biological: VCAR33
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Acute Leukemia, AML, Leukemia, Myeloid

More Information

Description: To determine the safety and maximum tolerated dose (MTD) of VCAR33 in patients with relapsed or refractory acute myeloid leukemia (R/R AML) after allogeneic hematopoietic cell transplantation (alloHCT)
Study Contact: Tatum Mistic - misti003@umn.edu
Principal Investigator: Joseph Maakaron
Phase: PHASE1
IRB Number: STUDY00021822